Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Hepatoblastoma Clinical Trials

A listing of Hepatoblastoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (16) clinical trials

First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer

This is a First in Human study of a new single agent (MTL-CEBPA) in patients with advanced cancer of the liver. The study is in two parts: dose escalation followed by a dose expansion; both parts of the study will recruit advanced hepatocellular carcinoma patients with cirrhosis. All participants will ...

Phase

Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma, esophageal cancer and malignant melanoma. Patients must be positive for HLA-A02:01 or HLA-A02:06 and the ...

Phase

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD133 (cluster of differentiation antigen 133 ) vector (referred to as CART-133 cells). II. Determine duration of in vivo survival of CART-133 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will ...

Phase

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Magnetic Resonance (MR)-guided high intensity focused ultrasound (HIFU) is an innovative technique that allows for non-invasive thermal ablation of tissue. Advantages over conventional local tumor control such as surgery, radiation, or radiofrequency are that MR-HIFU is completely non-invasive, non-ionizing, and enables ablation of large tumor volumes with avoidance of adjacent ...

Phase

Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer

Each cycle will last for 4 weeks. Sorafenib and trametinib will be administered orally on continuous basis. During the first cycle sorafenib will be started on day 1 and trametinib on day 8 to improve tolerance. Participants will get restaging scans every 2 cycles. Participants will continue to receive treatment ...

Phase

NAC to Prevent Cisplatin-induced Hearing Loss

The study is a dose-finding study of N-acetylcysteine (NAC) to protect hearing in children receiving cisplatin for the treatment of their cancer. NAC also has potential to protect the kidneys from cisplatin toxicity. The study uses a 3+3 dose-escalation scheme to determine the dose of NAC necessary to achieve serum ...

Phase

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

Chemotherapy resistance is a major cause of treatment failure in pediatric solid tumors. STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that promotes tumor proliferation, metastasis and chemotherapy resistance. Pediatric solid tumors such as neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, and central nervous system (CNS) tumors such ...

Phase

Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function

Study Groups and Radiation Administration: If you are found to be eligible to take part in this study, you will be assigned to a dose level of radiation based on when you join this study and on your screening test results. The dose level of radiation measures how much radiation ...

Phase

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

The molecular target for ET1402L1-CART is alpha fetoprotein (AFP), which is expressed on 60-80 percent of hepatocellular carcinoma (HCC). ET1402L1-CART is a second generation (CD28/CD3) chimeric antigen receptor (CAR) engineered with a human single-chain variable antibody fragments (scFv) against the anti-HLA-A02/AFP complex. This clinical study evaluates the safety and pharmacokinetics ...

Phase

A Study of CDX-1140 in Patients With Advanced Solid Tumors

CDX-1140 is a fully human monoclonal antibody that binds to a cell receptor called CD40 found on certain cells to activate the immune system which may promote anti-tumor effects. This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140. Eligible patients that ...

Phase